Schering-Plough Expands Discovery Operations

Schering-Plough has expanded discovery operations in Cambridge, MA with a new research facility to support the discovery and development of new therapeutic treatments. The state-of-the-art lab will accommodate approximately 200 scientists and support staff, more than twice that of the prior Cambridge location, and it provides more than triple the amount of lab space.

“This new facility is another demonstration of our long-term commitment to research-based health innovation. It also is evidence of our growing engagement in the science community of Cambridge, which with neighboring Boston has become one of the world’s premier research hubs for life science discoveries,” said Fred Hassan, Schering-Plough chairman and chief executive officer. “This kind of investment in discovery research is an engine of innovation at Schering-Plough for improved health for patients for the future.”

Schering-Plough Research Institute (SPRI) Cambridge focuses on the early stages of the drug discovery process, conducting research to develop a portfolio of small molecule drugs and provide efficiency in lead discovery through the use of proprietary affinity-based screening technologies and an integrated chemistry library.

“The greater Boston area is a vibrant and stimulating scientific environment. Our SPRI scientists benefit from the proximity of major academic institutions and leading biotechnology companies based nearby,” said Thomas D. Koestler, Ph.D., executive vice president, Schering-Plough and president, SPRI. “SPRI Cambridge, along with our research facilities in NJ and CA, is part of an integrated drug discovery organization that is developing an important pipeline of potential new medicines.”